Botulinum Toxin Type B
Cerebral Palsy
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCPhase 2/3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Cerebral Palsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE University of California, Los Angeles | Phase 4 | BB |
Bxcl501 Joseph Cravero | Phase 4 | BB |
LAMOTRIGINE Sathbhavana Brain Clinic | Phase 4 | BB |
TRIHEXYPHENIDYL Sathbhavana Brain Clinic | Phase 4 | BB |
Tetrabenazine Sathbhavana Brain Clinic | Phase 4 | BB |
View all 23 →
Same molecule, other indications
Botulinum Toxin Type B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →